期刊
ANTIVIRAL RESEARCH
卷 178, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2020.104780
关键词
Influenza; M2; Viroporin; Drug discovery; Electrophysiology; Drug resistance
资金
- Canadian Institutes for Health Research (CIHR) [PJT-153057]
- NIH [AI119187, AI144887]
The ongoing threat of seasonal and pandemic influenza to human health requires antivirals that can effectively supplement existing vaccination strategies. The M2 protein of influenza A virus (IAV) is a proton-gated, protonselective ion channel that is required for virus replication and is an established antiviral target. While licensed adamantane-based M2 antivirals have been historically used, M2 mutations that confer major adamantane resistance are now so prevalent in circulating virus strains that these drugs are no longer recommended. Here we review the current understanding of IAV M2 structure and function, mechanisms of inhibition, the rise of drug resistance mutations, and ongoing efforts to develop new antivirals that target resistant forms of M2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据